3H Health Investment, Loyal Valley and Morningside Lead USD54m Series B+ for China’s Alebund
Source(s): Alebund Pharmaceuticals
3H Health Investment, Loyal Valley Capital and Morningside Ventures led a USD54.5m Series B+ for Alebund Pharmaceuticals, a China-based biopharmaceutical company developing treatment for renal diseases, with participation from YuanBio Venture Capital, Octagon Capital, Verition Fund Management and HT Capital, and follow-on from Lilly Asia Ventures, Quan Capital, 3E Bioventures Capital and Sherpa Healthcare Partners. Read more